Umer Raffat

can you speak to your confidence overall heading into this interim? And is it fair to say that the size of the indication is generally similar with triple-negative breast

I noticed a $39 million sales number in 3Q. And I'm trying to make sense of it. By my rough math, it sounds like about 3,000 patients initiated in 3Q

In a scenario where the industry does converge around an MFN proposal, which is focused on Medicaid, how do you see the impact to Gilead business

how many of those nine cases had -- of ICANS had tremors, bradykinesia, or any other motor dysfunction

I'm just trying to think out loud what the long-term implications of that could look like, especially with all the competition coming

there's a lot of commentary on some of the expectations you've laid out on orforglipron pricing framework. If you could expand on that

on the more important ITT-like treatment estimand, orfo is tracking at 9% placebo adjusted. Oral sema is almost 14% placebo adjusted

Could you confirm there was no numerical imbalance on ALT above 5x? And on diarrhea, I recall it was in the low to mid-20s across the second highest and highest dose

there's one trial in particular I noticed has not been initiated or may not be in the plans, which is an outcomes trial

trying to balance today the fact that you are laying out a $70 billion non-risk adjusted revenue opportunity

It sounds to me like that's a little longer than I would have expected to get the readout out there on 150-patient trial

can we reasonably assume everything is, in fact, on track and you are still in a position

are you intending to keep the IP KEYTRUDA sub q here in US? Rather than Ireland as we head towards

do you feel reasonably comfortable that WINREVAIR can grow about 100% year-over-year from the fourth quarter